糖尿病病:关于治疗缓慢进展的支柱的更新
Sandra C Naaman1, George L Bakris1
1Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL.
糖尿病病 (DKD) 管理现在使用支柱式方法,结合SGLT2抑制剂和MRA等疗法,以准多个途径. 这一战略旨在减少残留风险并改善患者的治疗结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DKD) 管理已经随着对其复杂的病理生理学的理解而发展,涉及血液动力学,代谢和炎症途径.
- 雷宁-血管素系统阻塞是基石,但留下了残留风险.
- 像SGLT2抑制剂和MRAs这样的新药已经改变了范式.
结论:
- 支柱式方法代表了DKD治疗的重大进步,超越了单剂疗法.
- 根据结果证据优化组合疗法对于减缓病进展至关重要.
- 对GLP-1RA等药物的进一步研究可能为DKD患者提供额外的好处.
更多相关视频
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
05:06Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
相关概念视频
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Drug Therapy
Antianxiety Medications
